Modafinil Generis (Modafinil)

Modafinil is a central nervous system stimulant indicated for sleep‑related disorders that cause excessive daytime sleepiness.

• Narcolepsy: reduces daytime sleep attacks and improves alertness.
• Obstructive sleep apnea‑related excessive daytime sleepiness: lessens sleepiness in patients using appropriate apnea therapy.
• Shift work sleep disorder: helps maintain wakefulness during scheduled work periods.
• Excessive daytime sleepiness associated with other sleep disorders: supports wakefulness when other treatments are insufficient.

• Modafinil promotes wakefulness primarily by inhibiting the reuptake of dopamine, thereby increasing extracellular dopamine concentrations in brain regions that regulate arousal. It also enhances orexinergic signaling and modulates histamine and norepinephrine pathways, contributing to heightened alertness without the pronounced sympathomimetic effects seen with traditional stimulants.

Modafinil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often reported during early treatment.
• Nausea: transient stomach upset that usually resolves with continued use.
• Insomnia: difficulty falling or staying asleep, especially if taken later in the day.
• Dry mouth: reduced salivation leading to a feeling of oral dryness.

Serious or Rare Side Effects

• Rash or severe skin reactions: may indicate Stevens‑Johnson syndrome and require immediate medical attention.
• Psychiatric symptoms: new or worsening anxiety, depression, or hallucinations.
• Cardiovascular events: chest pain, palpitations, or hypertension that should be evaluated promptly.

Before prescribing Modafinil Generis, clinicians should consider several safety factors.

• Assess cardiovascular status: evaluate blood pressure and heart disease before initiating.
• Monitor psychiatric history: exercise caution in patients with anxiety, mood disorders, or psychosis.
• Avoid abrupt discontinuation: taper under medical supervision to reduce rebound sleepiness.
• Use caution in hepatic impairment: dose adjustment may be required.
• Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Modafinil Generis can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels of Modafinil.
• CYP3A4 inducers (e.g., rifampicin): may reduce Modafinil effectiveness.
• Oral contraceptives: may lower hormonal efficacy, increasing risk of breakthrough bleeding.

Moderate Interactions (Monitor Closely)

• Antidepressants (SSRIs): may increase the risk of insomnia.
• Antihypertensives: may blunt blood‑pressure control, necessitating closer monitoring.